Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Next Previous
Trial Profile

A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CP 101 Finch Therapeutics Group (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PRISM 3
  • Sponsors Crestovo; Finch Research & Development

Most Recent Events

  • 31 Mar 2022 According to a Finch Therapeutics Group media release, data will be presented at Digestive Disease Week (DDW) 2022.
  • 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
  • 27 Oct 2021 Results assessing CP101 engraftment drives efficacy for prevention of recurrent C. difficile Infection, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top